AbbVie (ABBV) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of ...

AbbVie (ABBV) rebounds after losses, gaining ~% as analysts stay bullish. Discover why its obesity drug deal boosts long-term ...

AbbVie has filed a lawsuit against Genmab, accusing the Danish drugmaker of being “intentionally and willfully blind” to the ...

Genmab denies the accusation that it knowingly stole confidential information in a $1.8 billion deal to acquire a cancer drug ...

As AbbVie accuses Genmab of unlawfully using proprietary ADC technology, find out about their collaboration and the dispute ...

AbbVie claims that Genmab turned a blind eye to trade secret theft allegedly used to support the development of ProfoundBio’s ...

Imagine standing on a vast, dark plain. Without light, you cannot see dips and rolls in the grass or make out hills and ...

Under the new collaboration, OpenFold will produce a fine-tuned version of its model that’s trained on AbbVie and Johnson & ...

Bearish flow noted in AbbVie (ABBV) with 8,035 puts trading, or 3x expected. Most active are 4/4 weekly 207.5 puts and 3/28 weekly 212.5 calls, ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

The latest trading day saw AbbVie (ABBV) settling at $209.17, representing a -0.4% change from its previous close.

AbbVie (NYSE: ABBV) today announced that new data from its early oncology research will be showcased across multiple presentations at the upcoming American Association of Cancer Research (AACR) Annual ...